Two names, one scaffold — where the confusion starts

Searching for either name turns up overlapping results, clinic pages that use both interchangeably, and the nagging sense that one might be a newer or superior version of the other. In practice, neither is true.

At the centre of both names sits the same material: ChondroFiller®, a CE-marked Class III medical device manufactured by Meidrix Biomedicals GmbH in Germany and in commercial clinical use since 2013. It is an acellular, injectable Type I collagen scaffold — sourced from murine collagen — that gels rapidly once placed inside a joint. There is no separate 'Liquid Cartilage' product with different ingredients.

Liquid Cartilage™ is a clinical brand name applied to a treatment pathway that uses the ChondroFiller® scaffold as its structural component, combined with additional biological elements and delivered in a different setting. A further layer of confusion arises because some clinical platforms use the phrase 'Liquid Cartilage injections (ChondroFiller)' as a lay descriptor for a straightforward injectable treatment — with no additional biological component at all.

The distinction that genuinely matters, then, is not what the scaffold is made of but how it is delivered, in what clinical setting, and whether anything else is added. Those differences are what the sections below address.

How ChondroFiller injection works as a standalone treatment

The appointment itself is straightforward: a single outpatient visit in which the ChondroFiller solution is placed under ultrasound guidance directly into the affected joint. No theatre admission, no general anaesthetic, and no surgical incision are involved.

Once delivered, the collagen solution gels rapidly in place, forming a layer across the articular surface. It functions as an added cushion over worn cartilage rather than excavating and replacing what is already there.

The underlying mechanism is acellular matrix-induced chondrogenesis. The scaffold contains no cells of its own; instead, once positioned, it acts as a structural and signalling framework that draws the patient's own progenitor cells — from the synovium and subchondral bone — into the treated area to support the body's own repair processes. Importantly, the mechanical cushioning effect does not wait for that cellular response: the gelled collagen acts as a protective layer from the moment it sets.

Because the treatment's immediate protective function does not depend on how actively the patient's body regenerates new tissue, it carries no upper age limit and no defect-size restriction. This is a meaningful clinical distinction from approaches that rely entirely on endogenous regeneration, where patient age and the extent of remaining healthy cartilage can determine whether treatment is appropriate at all.

Safety data from more than 19,000 treated cases show zero serious adverse device effects and a device complaint rate of 0.06%.

What Liquid Cartilage™ adds to that scaffold

Adding the patient's own medicinal signalling cells changes both the ambition and the eligibility criteria of the treatment.

In the Liquid Cartilage™ pathway, the ChondroFiller® scaffold is not delivered alone. It is co-administered alongside cells drawn from the patient's own bone marrow, fat tissue, or platelet-rich fibrin — sources rich in mesenchymal signalling cells that, once introduced into a collagen matrix, can undergo chondrogenic differentiation and begin producing cartilaginous tissue. Peer-reviewed laboratory work confirms that mesenchymal cells migrate actively into Type I collagen scaffolds and begin laying down cartilaginous matrix — the biological rationale that underpins this combination approach. Rather than relying solely on the body's own progenitor cells migrating to the scaffold after placement, this pathway brings additional signalling cells directly to the repair site.

Because the approach targets a specific focal area of damage, the preparation of that site is more involved than in the standalone injection pathway. This makes it a distinct alternative clinical route — not an outpatient injection appointment — suited to a carefully selected patient group.

That selectivity is the defining feature. Liquid Cartilage™ is reserved for focal, contained defects where the surrounding cartilage is reasonably intact and the patient retains enough regenerative capacity for the cellular component to be effective. It is not a broader-access substitute for the injection but an upgrade pathway for cases that exceed what the scaffold alone can address — either because the defect is too complex or because the clinical picture warrants additional biological support.

The two routes are therefore complementary. The injection is the wider-access starting point; this more demanding pathway sits alongside it for patients whose presentation calls for a higher level of biological intervention.

Which patients typically suit each pathway

Those differences in mechanism and eligibility — set out in the sections above — translate into a practical split worth understanding at the point of deciding whether to seek an assessment.

The injection pathway has broad reach. Patients with diffuse or generalised cartilage wear, those who may not retain strong regenerative capacity, and anyone who needs or prefers an outpatient route are all candidates for assessment. There is no ceiling based on age or the extent of wear — criteria that exclude many patients from other cartilage interventions simply do not apply here.

The combined scaffold-and-cell pathway is reserved for a narrower group: typically younger patients with a focal, contained lesion at a site where the surrounding joint surface is reasonably preserved. Whether a patient retains enough regenerative capacity to benefit from the cellular component is a clinical judgement that can only be made after imaging and examination.

Both pathways are self-funded private treatments — neither is available on the NHS, and neither is covered by private medical insurance — so confirming that practical reality before pursuing an assessment is sensible.

Formal specialist review, not marketing material, is the appropriate basis for any decision. Cartilage damage is highly individual, and self-selecting between pathways based on descriptions alone is not a reliable route.

One direct question is worth putting to any clinic at the point of enquiry: is the procedure the injectable collagen scaffold alone, or does it include cellular co-delivery? Given the naming overlap that exists in this area, the answer removes ambiguity and clarifies exactly what is being offered.

What the evidence currently shows

The clearest outcomes data for the ChondroFiller® scaffold concerns knee function: patient-reported IKDC scores improve by approximately 30 points at 12 months — a margin considered clinically meaningful — based on clinical investigations cited in the manufacturer's 2025 Clinical Evaluation Report. That figure comes from manufacturer-supported work rather than independent randomised trials, which is the appropriate context in which to read it. On safety, the real-world dataset covered in the earlier section is large and consistent; no serious adverse device effects have been recorded across its scope, providing a reassuring baseline for patients assessing procedural risk.

The evidence picture is less complete for the Liquid Cartilage™ combined pathway. No randomised head-to-head data comparing the standalone injectable scaffold against the scaffold-plus-MSC protocol exists in the published literature. The cellular co-delivery component also lacks independent peer-reviewed outcome evidence specific to this combination protocol; the biological rationale is grounded in peer-reviewed laboratory work confirming that mesenchymal cells migrate into Type I collagen scaffolds and produce cartilaginous matrix, but that is not equivalent to a clinical outcomes dataset for the procedure itself.

Long-term durability is a further open question. Published outcome data extending beyond two years has not been reported for either pathway in the clinical literature. For a patient weighing the standalone injection against the more involved combined procedure, that gap is practically significant: the durability argument — whether the cellular component extends the benefit window enough to justify the additional complexity — cannot yet be made from published evidence. Asking a specialist what follow-up data exist for cases with a comparable cartilage profile is therefore one of the most useful questions to bring to an assessment.

Finding a specialist who offers collagen scaffold injection

Both pathways are available only through private specialist care — no GP referral is required, but a structured consultation is the entry point, and it is where the naming ambiguity that runs through this area finally resolves. Search MSK lists specialists across the UK who offer ChondroFiller collagen scaffold injection; filtering by region and specialty is a practical way to find one whose caseload matches your situation.

At that first contact, one question does most of the work: is what is being offered the injectable scaffold alone, or does it include cellular co-delivery? Treatment names in this area overlap enough that asking directly is more reliable than inferring from a clinic's website. The answer also reveals which eligibility criteria apply — and, in doing so, turns five sections of background reading into a single, actionable clinical conversation.